Taming an unruly target in diabetes

April 4, 2018 by William Weir, Yale University
Topological map of a toxic pore formed by hundreds of copies of the hormone IAPP. Credit: Yale University

Focusing on a simple hormone in us all, a Yale researcher has found specific forms of it that poke toxic holes in cells—a discovery that he is leveraging into a treatment for patients with diabetes.

The research, published April 3 in Nature Communications, is also central to the recent awarding of two grants totaling $600,000 from the Connecticut Bioscience Innovation Fund and the Blavatnik Fund for Innovation at Yale.

Andrew Miranker, a professor of molecular biophysics and biochemistry and of chemical & environmental engineering, and his team will use these funds to translate the discoveries into novel therapies for type 2 diabetes. Part of this effort includes the formation of a new biotechnology company, ADM Therapeutics, based in Connecticut. Although the researchers are currently focusing on type 2 diabetes, the approaches they developed also apply to Alzheimer's and Parkinson's diseases.

Type 2 diabetes is a degenerative ailment that affects hundreds of millions of people worldwide. Its progression is tied directly to the health of in the islets—groups of cells in the pancreas. These cells carefully coordinate the release of insulin in response to changes in . Failure of these cells plays a significant role in the cause of the disease as the body loses the ability to regulate blood glucose. Currently available drugs work by stimulating alternative ways for the body to use or eliminate glucose. There are no approved drugs available to address the causes of type 2 diabetes.

Miranker's lab is focused on a protein partner to insulin. The protein, known as islet amyloid polypeptide (IAPP), is also a hormone made by these same cells. The group has discovered that when IAPP adopts the wrong shape, it pokes holes in the membranes of islets large enough to kill the insulin-secreting cells.

"If we ameliorate these very large holes by designing a compound to target a particular IAPP structure, we can prevent toxicity," said Miranker.

IAPP works alone in its healthy state, but the toxic version of IAPP is formed from tens to hundreds of copies of the protein. This sprawling structure poses a formidable challenge, note the researchers, and controlling it requires an approach very different from those of traditional drugs. Finding a drug to close a specific toxic hole should be a simple matter of finding the one square peg among round pegs, Miranker said, but mused, "What if your target is more like a porous pile of spaghetti than a hole?"

"Instead of thinking of a protein disease target as a rigid object with a well-defined pocket to aim at, you make the drug extremely well-defined and rigid, and you demand the protein adopt a structure to interact with it," Miranker said. This amounts to designing a drug that acts like a fork for the spaghetti to wrap around, he said, noting, "you can't eat spaghetti with a spoon."

To that end, the Miranker lab has developed a drug lead, ADM-116, that binds to IAPP and can rescue cells that make insulin. The water-soluble ADM-116 crosses the outer cell membrane, finds IAPP, and winds it up. By doing so, ADM-116 prevents IAPP from punching a hole in a sensitive internal cell membrane. Miranker and his team, and ultimately his Connecticut-based company, will translate these discoveries into drugs that improve the long-term health of these .

Miranker has been studying how changes in protein shape can result in toxicity for more than 20 years. Only now has this work reached a stage where his team can build off these fundamentals and apply it to human health. Miranker noted that the $500,000 grant from Connecticut Bioscience Innovation Fund, awarded in January, and last year's $100,000 grant from the Blavatnik Fund for Innovation at Yale were essential to making this leap.

Christopher Unsworth, associate director of business development for the Yale Office of Cooperative Research, said the promise of Miranker's research is that he takes such a different approach to the problem.

"His lab has developed a whole range of techniques to evaluate what is going on with these proteins and then designed a compound that could interfere with that process," he said. "A lot of times, we see basic research that identifies novel mechanisms that may be related to a disease, but understanding those mechanisms doesn't necessarily take you to a . Andrew's work, though, is directed pretty much toward chemical matter that could be a potential therapeutic."

Explore further: Toxic proteins and type 2 diabetes

More information: Conformational switching within dynamic oligomers underpins toxic gain-of-function by diabetes-associated amyloid. Nature Communications, DOI: 10.1038/s41467-018-03651-9

Related Stories

Toxic proteins and type 2 diabetes

March 9, 2018
Nearly a half-billion people worldwide live with type 2 diabetes. Yet despite the disease's sizeable and increasing impact, its precise causes remain murky. Current scientific thinking points to two key processes: insulin ...

Researchers demonstrate transmission of diabetes symptoms via prion-like mechanism

August 1, 2017
Researchers from McGovern Medical School at The University of Texas Health Science Center at Houston have discovered that the symptoms of diabetes can be induced by a misfolded form of a pancreatic protein. The findings, ...

Researchers find mechanism that clears excess of protein linked with Type 2 diabetes

July 19, 2014
People with Type 2 diabetes have an excess of a protein called islet amyloid polypeptide, or IAPP, and the accumulation of this protein is linked to the loss of insulin-producing pancreatic beta cells.

Recommended for you

Does diabetes damage brain health?

December 14, 2018
(HealthDay)—Diabetes has been tied to a number of complications such as kidney disease, but new research has found that older people with type 2 diabetes can also have more difficulties with thinking and memory.

Researchers study abnormal blood glucose levels of discharged patients

December 14, 2018
University of Minnesota Medical School researchers decided to delve into an area where little data currently exists. They wanted to know what happens after these patients with abnormal blood glucose measurements are discharged? ...

Researchers zero in on potential therapeutic target for diabetes, associated diseases

December 14, 2018
A recent study led by researchers in Texas A&M University's department of nutrition and food science shows how a novel regulatory mechanism serves as an important biomarker for the development of diabetes, as well as a potential ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Millions of low-risk people with diabetes may be testing their blood sugar too often

December 10, 2018
For people with Type 2 diabetes, the task of testing their blood sugar with a fingertip prick and a drop of blood on a special strip of paper becomes part of everyday life.

Very low calorie diets trialled by NHS to tackle diabetes

December 7, 2018
Hundreds of thousands of people will receive NHS help to battle obesity and type 2 diabetes under radical action set out by Simon Stevens, Chief Executive of NHS England.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.